Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized parallel-group, placebo-controlled, double-blind, multi-center trial to eValuate the effIcacy and safeTy of the orAL sGC stImulator vericiguaT to improve phYsical functioning in activities of daily living in patients with heart failure and preserved ejection fraction (VITALITY-HFpEF)

Next Previous
Search
Trial Profile

A randomized parallel-group, placebo-controlled, double-blind, multi-center trial to eValuate the effIcacy and safeTy of the orAL sGC stImulator vericiguaT to improve phYsical functioning in activities of daily living in patients with heart failure and preserved ejection fraction (VITALITY-HFpEF)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vericiguat (Primary)
  • Indications Chronic heart failure
  • Focus Therapeutic Use
  • Acronyms VITALITY-HFpEF
  • Sponsors Bayer

    • Most Recent Events

    • 04 Apr 2022 Results of an analysis assessed examined the correlation between self-reported frailty (Fried Frailty Index) and the KCCQ-PLS and 6MWD in 761 patients presented at the 71st Annual Scientific Session of the American College of Cardiology
    • 20 Oct 2020 Primary endpoint (Change in KCCQ physical limitation score from baseline to week 24) has not been met according to the results published in the JAMA: the journal of the american medical association
    • 20 Oct 2020 Results assessing the efficacy of the oral soluble guanylate cyclase stimulator vericiguat on the physical limitation score (PLS) of the Kansas City Cardiomyopathy Questionnair published in the JAMA: the Journal of the American Medical Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top